images (1)

primobolan for women

Has detoxification (including in relation to the products of ethyl alcohol metabolism, heavy metals and their compounds, arsenical compounds) action. In clinical studies have shown hepatoprotective and antioxidant properties of dimercaprol.
The active sulfhydryl groups dimercaprol interact with thiol poisons and products of metabolism of alcohol (ethanol) that primobolan for women are in the blood and tissues, form a non-toxic compound with them (complexes) that are excreted in the urine. When you receive the drug orally active agent dimercaprol with portal blood enters the liver, where it rapidly and irreversibly binds to acetaldehyde, which causes the subsequent removal of ethyl alcohol from other organs and tissues. Dimercaprol also activates acetaldehyde dehydrogenase, increasing ethanol oxidation and detoxification of toxic products of its enzymatic system of the liver. The presence of calcium pantothenate in the composition of the drug enhances the detoxification effect of dimercaprol. Pantothenic acid is involved in carbohydrate and fat metabolism, stimulates the formation of corticosteroids accelerates regeneration.

Pharmacokinetics
Following oral administration of a capsule containing 250 mg of sodium 2,3-dimerkaptopropansulfonata maximum concentration in the blood is reached after 1.5 hours or is between 90-140 mg / liter. The average residence time of the drug in the body 9-11 h (10,16 ± 0,39 h), including: in the gastrointestinal tract – 15-20 minutes. The half-life (T1 / 2) was 7,5 ± 0.46 h. Calcium pantothenate is well primobolan for women absorbed in the gut and is cleaved, releasing the pantothenic acid. About 60% of the drug is excreted in the urine, partly with feces.

Indications

  • Alcohol withdrawal syndrome (for the prevention and treatment of a hangover);
  • alcoholism (in the complex therapy);
  • acute and chronic poisoning with organic and inorganic arsenic compounds, mercury, gold, chromium, cadmium, cobalt, copper, zinc, nickel, bismuth, antimony, cardiac glycoside intoxication.

Contraindications

  • Hypersensitivity to the drug, severe decompensated liver disease and kidney;
  • Children up to age 18 years.

Precautions
Be wary of low blood pressure.

Pregnancy and lactation
Data on the use of the drug during pregnancy and lactation is not. Due to the lack of necessary information, the use during pregnancy and lactation is contraindicated.

Dosing and Administration
Inside. Swallow capsules 30 minutes before a meal, not liquid, squeezed water. To prevent a hangover – after drinking 1 capsule (250 mg + 10 mg) in the evening before bedtime.

For the treatment of alcohol withdrawal syndrome: 1 capsule (250 mg + 10 mg) 1-2 times a day (doses given in primobolan for women terms of dimercaprol, and calcium pantothenate). If necessary, the daily dose can be increased to 750 mg (for dimercaprol) and dosing frequency should be adjusted to 3 times a day.

The drug should be taken 3-7 days before the termination of the symptoms of intoxication. In alcoholism: 1 capsule (150 mg ± 7 mg) 1-2 times a day for 10 days (doses given in terms of dimercaprol, and calcium pantothenate). When poisoning arsenic compounds and heavy metal salts 300-1000 mg (as sodium dimerkaptopropaisulfonatu) per day for 2-3 hours, for 7-10 days.

Side effects:
Rare: allergic reactions (pruritus, urticaria, rash on the skin and mucous membranes, mucosal edema, genital itching, stomatitis).

Very rare: allergic reactions by type of angioedema or Stevens-Johnson syndrome (a sudden increase in body temperature, malaise, spotty-vesicular or bullous rash on skin and mucous membranes of the mouth, genitals, anus). In this case, you should stop taking the drug and consult a doctor.

The risk of allergic reactions is higher in people with asthma or allergies in history. When used in high doses: nausea, dizziness, tachycardia, paleness of skin.

Overdose
Manifestations of overdose can occur if the recommended dose is exceeded more than 10 times.

The symptoms: shortness of breath, hyperkinesis, confusion, lethargy, stupor, intermittent convulsions.

Treatment: gastric lavage, administration of activated charcoal, laxatives, symptomatic therapy, in severe cases, oxygen therapy, administration of dextrose.

Interaction with other medicinal products
incompatible with pharmaceutical preparations containing salts of heavy metals, as well as with alkalis (quickly decomposes).

Cautions Effects on ability to drive vehicles and management mechanisms: the drug does not affect the performance of potentially hazardous activities that require attention and quick, reactions (driving and other vehicles, work with moving machinery, the work manager and operator, etc. )..

Form Release
Capsules 150 mg ± 7 mg, or 250 mg ± 10 mg.
At 2, 5 capsules (250 mg + 10 mg) or 10 capsules (150 mg ± 7 mg) in blisters of PVC film and aluminum foil printed patent. 1 contour cell pack of 10 capsules (150 mg ± 7 mg), 1 contour cell package 2 capsules (250 mg + 10 mg) or two blisters 5 capsules (250 mg + 10 mg), together with instructions for use placed a stack of cardboard.

Storage:
Store in a dark and dry place at a temperature no higher than 25 ° C. Keep out of the reach of children.

Shelf life
2 years. Do not use beyond the expiration date printed on the package.

Conditions of supply of pharmacies
without a prescription. Running low dose t3 clen cycle trying to lose bodyfat isn’t a real hot idea imo.

images (2)

primobolan results

It has no effect on the release of pituitary hormones gonadotropin, thyroid-stimulating hormone, and somatotropin. It does not affect the concentrations of cortisol, aldosterone, androgen or estrogen, sperm motility, sperm quantity and composition, as well as does not have antiandrogenic actions. It may primobolan results weaken the release of vasopressin. Increases gastric mucosal protective mechanisms and helps heal her injuries associated with exposure to hydrochloric acid (including cessation of gastrointestinal bleeding and scarring of stress ulcers), by increasing the formation of gastric mucus, its content of glycoproteins, stimulating the secretion of bicarbonate gastric mucosa endogenous synthesis of prostaglandins in it and recovery rate.At a dose of 150 mg suppresses gastric acid secretion for 8-12 hours. Inhibits microsomal enzymes.

 

Treatment and prevention of gastric ulcers and 12 duodenal ulcer, NSAID-gastropathy, heartburn (associated with hyperacidity), hypersecretion of gastric juice, symptomatic ulcers, stress ulcers of the gastrointestinal tract (GIT), erosive esophagitis, reflux esophagitis, Zollinger-Ellison syndrome, systemic mastocytosis, multiple endocrine adenomatosis; dyspepsia, characterized by epigastric or retrosternal pain associated with eating or disturbs sleep but not caused by the above conditions; treatment of bleeding from the upper gastrointestinal tract, prevention of recurrence of gastric bleeding in the postoperative period; prevention of aspiration of gastric juice in patients who carried out the operation under general anesthesia (Mendelson’s syndrome); prevention of aspiration pneumonitis; as adjuvant therapy in the treatment of rheumatoid arthritis.

Contraindications
: Hypersensitivity to ranitidine or other components of the drug.
Pregnancy, lactation.
Children under 12 years old.

Precautions
Renal and / or hepatic failure, cirrhosis with encephalopathy (disorder), acute porphyria (also in history), immunosuppression.

Dosing and Administration
Inside adults and children over 12 years, regardless of the meal, not liquid, squeezed small amounts of liquid.

Peptic ulcer and 12 duodenal ulcer. For the treatment of exacerbations appoint 150 mg 2 times a day (morning and evening) or 300 mg at night. If needed – 300 mg 2 times a day. Course duration lecheniya- 4-8 weeks. For the prevention of relapse appoint 150 mg at night.

NSAID gastropathy. At 150 mg two times daily or 300 mg at night for 8-12 weeks. Prevention of the formation of ulcers when taking NSAIDs – 150 mg 2 times a day.

Postoperative ulcer. According 150 mg 2 times a day for 4-8 weeks.

Gastroesophageal reflux disease. 150 mg 2 times a day, or 300 mg at night if required dose can be increased up to 150 mg four times a day. The course of treatment 8-12 weeks. When I-II art. the severity of reflux esophagitis, increase the dose to 600 mg / day in 4 divided doses for 12 weeks. Long-term prophylactic therapy -150 mg 2 times a day

Zollinger-Ellison syndrome. The initial dose of 150 mg three times a day dose may be increased to 6 g / day, if necessary.

Prophylaxis of recurrent bleeding. 150 mg 2 times a day.

Prophylaxis of Mendelson’s syndrome. Assign a dose of 150 mg 2 hours before anesthesia, and preferably also 150 mg the previous evening.

Episodes in chronic dyspepsia – 150 mg 2 times a day for 6 weeks.
Babies for treating peptic ulcers – inside, 2-4 mg / kg two times a day; with reflux esophagitis 2-8 mg / kg 3 times a day; the maximum daily dose – 300 mg.

Patients with impaired renal function require correction mode. When creatinine clearance less than 50 ml / min, the recommended primobolan results dose is 150 mg per day, the presence of concomitant liver function abnormalities may require further dose reduction. Patients who are on hemodialysis, another dose administered immediately after hemodialysis.

Side effect From the digestive system: nausea, dry mouth, constipation, vomiting, diarrhea, abdominal pain; rarely – hepatocellular, cholestatic or mixed hepatitis, acute pancreatitis.

From the side of hematopoiesis: leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, bone marrow hypo- and aplasia of immune hemolytic anemia.

Cardio-vascular system: decrease in blood primobolan results pressure, bradycardia, arrhythmias, AV-block.

From the nervous system: fatigue drowsiness; rare – confusion, tinnitus, irritability, hallucinations (mainly in the elderly and critically ill patients), involuntary movements.

From the senses: blurred vision, paresis of accommodation.

From the musculoskeletal system: arthralgia, myalgia.

From endocrine system: hyperprolactinemia, gynecomastia, amenorrhea, decreased libido, impotence.

Allergic reactions: urticaria, skin rash, angioedema, anaphylactic shock, bronchospasm, erythema multiforme.

Other: alopecia, hypercreatininemia.

Overdose
symptoms: convulsions, bradycardia, ventricular arrhythmias.
Treatment: symptomatic. It is shown that the induction of vomiting and / or gastric lavage. With the development of convulsions – diazepam intravenously, with bradycardia – atropine, ventricular arrhythmia – lidocaine. Hemodialysis is effective.

The interaction with other drugs
increases AUC (area under the concentration-time curve) and the concentration of metoprolol in the blood serum (respectively 80 and 50%), the T1 / 2 Metoprolol increased from 4.4 to 6.5 hours.

It reduces absorption of itraconazole and ketoconazole.

It inhibits hepatic metabolism phenazone, aminophenazone, diazepam, hexobarbital, propranolol, metoprolol, nifedipine, warfarin, diazepam, lidocaine, phenytoin, theophylline, aminophylline, indirect anticoagulants, glipizide, buformina, metronidazole, calcium channel blockers slow.

Increasing the concentration of procainamide.

Antacids, sucralfate slow down the absorption of ranitidine (while the application of the break between taking antacids and ranitidine should be at least 1-2 hours).

Drugs that suppress the bone marrow to increase the risk of neutropenia.

Smoking decreases the effectiveness of ranitidine.

Cautions
symptoms of peptic ulcer disease 12 duodenal ulcer may disappear within 1-2 weeks, but therapy should be continued for as long as the scarring is not confirmed by endoscopy or X-ray examination.

May mask symptoms associated with carcinoma of the stomach, so before starting treatment to rule out malignancy Ranitidine undesirable sharply cancel ( “ricochet” syndrome).

With long-term treatment of patients with weakened under stress may be bacterial lesions of the stomach and then spread the infection.

Blockers H 2 histamine receptors to be taken 2 hours after administration of ketoconazole or itraconazole avoid significant reduction of absorption. Can cause false positive reaction in the test of protein in urine.

Increases creatinine, GGT (gamma-glutamyl) and serum transaminases.

Protivodeystvodeystvuet influence on histamine and pentagastrin gastric acid-forming function, therefore, the foregoing test, it is not recommended for 24 hours.

Suppress skin reaction to histamine, thus leading to false-negative results (prior to diagnostic skin testing is recommended to stop to detect immediate allergic skin reaction such as drug use).

Efficacy in inhibiting nocturnal acid secretion in the stomach may decrease as a result of smoking.

During treatment should avoid eating foods, drinks and other drugs that can cause irritation of the gastric mucosa.

During the period of treatment must be careful when driving and occupation of other potentially hazardous activities that require high concentration and psychomotor speed reactions.

Composition
Tablets, film-coated, 150 mg and 300 mg.
10 tablets in a strip of aluminum foil laminated with polyethylene film nyzkoy density. 2 or 10 strips packed in a cardboard box with instructions for use.

Storage conditions
List B.
In dry, dark place at a temperature no higher than 25 ° C.
Keep out of reach of children!

Shelf life
3 years.
Do not use after the expiration date printed on the package.

Terms otpuskaiz pharmacies
without a prescription. how much to inject for weight loss

hcg diet

shots for weight loss reviews

images (3)

primobolan enanthate

Zoledronic acid belongs to the highly effective bisphosphonates, selective effect on bone. The drug suppresses bone resorption by acting on osteoclasts.The selective effect primobolan enanthate of bisphosphonates on bone is based on the high affinity for mineralized bone. The exact molecular mechanism for the inhibition of osteoclastic activity is still unclear. Zoledronic acid has no adverse effect on the formation, mineralization and bone mechanical properties.In addition to inhibitory effect on bone resorption zolendronovaya acid has antitumor properties providing efficacy in bone metastases:

  • In vivo: inhibition of osteoclastic primobolan enanthate bone resorption modifying bone marrow microenvironment resulting in a reduction of tumor cell growth; anti-angiogenic activity.Inhibition of bone resorption clinically including accompanied by a marked reduction of pain.
  • In vitro: Inhibition of osteoblast proliferation, direct cytostatic and pro-apoptotic activity, synergistic cytostatic effect with protivoopuhlevymi drugs; anti-adhesive / invasive activity. ®

 

Zoledronic acid, inhibiting proliferation and inducing apoptosis, has a direct anticancer effect against the human myeloma and breast cancer cells, but also reduces the penetration of breast cancer cells through a human extracellular matrix that indicates the presence of Her antimetastatic properties. Also, zoledronic acid inhibits proliferation of human endothelial cells and has an anti-angiogenic effect in animals.

Patients with prostate cancer and other solid tumors with metastatic bone lesions Zometa ® prevent the development of pathological fractures, spinal cord compression, reduces the need for radiation therapy and surgical interventions, reduces tumor hypercalcaemia. The drug can inhibit the progression of pain. The therapeutic effect is less pronounced in patients with osteoblastic centers than osteolytic. In patients with multiple myeloma and breast cancer in the presence of at least one bone hearth efficiency Zometa ® 4 mg is comparable with pamidronate 90 mg.

Patients with tumor hypercalcemia effect Zometa ® is characterized by a decrease in the level of calcium in the blood serum and excretion of calcium in the urine. The median time to normalization of calcium level is about 4 days. By the 10 th day of the calcium concentration to normal in 87-88% of patients. The median time to relapse (corrected for albumin serum calcium level at least 2.9 mmol / l) is 30-40 days. No significant differences between the effectiveness of Zometa ® at doses of 4 and 8 mg for treatment of hypercalcemia is observed.

Studies reveal no significant differences in the incidence and severity of adverse events observed in patients treated with Zometa ® at doses of 4 mg, 8 mg, pamidronate in a dose of 90 mg or a placebo in the treatment of bone metastases and hypercalcaemia.

Pharmacokinetics
Data on the pharmacokinetics of bone metastases were obtained after single and repeated 5 and 15-minute infusions of 2, 4, 8 and 16 mg zoledronic acid in 64 patients. Pharmacokinetic parameters are independent of dose.

After initiation of the infusion Zometa ® serum concentrations increased rapidly, reaching a peak at the end of infusion, followed by a rapid decrease in the concentration of 10% after 4 hours and less than 1% of the peak after 24 hours successively prolonged period of low concentrations not exceeding 0.1% of the maximum to re-infusion on day 28.

Zoledronic acid is infused intravenously, excreted by the kidneys in three phases: rapid biphasic elimination of the drug from the systemic circulation with half-lives of 0.24 hours and 1.87 hours, and long phase with a finite half-life of 146 hours, not mentioned drug accumulation after repeated administration every 28 days.. Zoledronic acid is not metabolized and excreted by the kidneys unchanged. During the first 24 hours in the urine detected 39 ± 16% of the administered dose. The remainder of the drug is mainly associated with bone tissue. Then reverse the release of zoledronic acid are fast enough from the bone into the systemic circulation and its excretion by the kidneys. The total plasma clearance of the drug is 5.04 ± 2.5 l / h and independent of dose, sex, age, race and weight of the patient. Increasing the infusion time from 5 minutes to 15 reduces the zoledronic acid concentration of 30% at the end of infusion, but no effect on AUC.

Pharmacokinetic studies in patients with hypercalcemia or failure of liver function have not been conducted. According to data obtained in vitro, zoledronic acid inhibits the enzyme and human P450 biotransformation, which suggests that the state of the liver any essential way affect the pharmacokinetics of zoledronic acid. Since feces derived less than 3% of the dose of the drug.

The renal clearance of zoledronic acid was positively correlated with creatine clearance and is 75 ± 33% of the creatinine clearance, averaging 84 ± 29% (range 22-143 mL / min) in the 64 patients included in the study. population analysis showed that patients with a creatinine clearance of 20 ml / min (severe renal failure) or 50 ml / min (moderate renal insufficiency) calculated clearance of zoledronic acid is 37% and 72% respectively of the value of the clearance zoledronic acid in patients with a creatinine clearance of patients 84 ml / min. Limited pharmacokinetic data obtained for patients with severe renal impairment (creatinine clearance less than 30 mL / min).

Results Zoledronic acid low affinity to blood components, plasma protein binding is low (about 56%) and independent of the concentration of Zometa ® .

Indications for use.

 

  • Bone metastases common cancers (prostate cancer, breast cancer), and myeloma, including reducing the risk of pathologic fractures, spinal cord compression, hypercalcemia due to tumors and to reduce the need for radiotherapy or surgical intervention on the bone.
  • Hypercalcemia due to malignancy.

 

Contraindications

 

  • Hypersensitivity to zoledronic acid, other bisphosphonates, or any other components of the drug.
  • Pregnancy and lactation.

 

Precautions
When deciding on the use of  in patients with hypercalcemia due to malignancy, on the background of renal function, it is necessary to evaluate the condition of the patient primobolan enanthate and make the conclusion that prevails whether the potential benefits of the introduction of the drug over the possible risk.

Before each dose Zometa ® should be determined in the serum creatinine concentration. At the beginning of treatment in patients with bone metastases with mild renal dysfunction and moderate severity, recommended Zometa ® at lower doses. In patients who have kidney dysfunction appeared during therapy Zometa ®, drug therapy can be continued only after the concentration of creatinine returns to the values that are within 10% of the initial value.

Given the possibility of renal impairment in the application of bisphosphonates, including Zometa ® , as well as due to lack of comprehensive data on the clinical safety of the drug in patients with severely impaired renal function (serum creatinine concentration> 400 mmol / L or> 4.5 mg / dL in patients with hypercalcemia due to malignancy and> 265 umol / l or> 3.0 mg / dL in patients with malignant tumors with metastases in the bone) and the presence of very limited pharmacokinetic data in patients with baseline severe renal impairment (creatinine clearance <30 mL / min ), the use of Zometa ® in these patients is not recommended.

Dosage and administration: Bone metastases common malignant tumors and multiple myeloma: Adults and elderly patients The recommended dose is 4 mg. Before administration of the drug diluted concentrate (contents of 1 vial) 100 ml of a solution for infusion containing no calcium (0.9% sodium chloride solution or 5% dextrose). Zometa administered intravenously; infusion duration – at least 15 minutes. The multiplicity of purposes – every 3-4 weeks.

 

Cautions
Before infusion should ensure adequate hydration of the patient. If necessary, we recommend the introduction of saline before, in parallel or after the infusion of Zometa ® Avoid overhydration patient because of the risk of complications to the cardiovascular system.

After the introduction of Zometa ® requires constant monitoring of the concentration of calcium, phosphorus, magnesium and creatinine in serum. With the development of hypocalcemia, hypophosphatemia, or hypomagnesemia may be necessary in the short-term additional administration of the substances concerned. Patients with untreated hypercalcemia usually has renal impairment, therefore careful monitoring of renal function in these patients.

When deciding on the treatment of Zometa ® patients with bone metastases, to reduce the risk of pathologic fractures, spinal cord compression, hypercalcemia due to tumors and to reduce the need for radiotherapy or surgical intervention on the bone, it should be appreciated that the therapeutic effect after 2-3 months after initiation of treatment Zometa ® .

There are some reports of impaired renal function during treatment with bisphosphonates. Risk factors for the occurrence of such complications include dehydration, previous renal failure, multiple doses of Zometa or other bisphosphonates, as well as use of nephrotoxic drugs, and too rapid introduction of the drug. Although the risk of complications is reduced above provided administration Zometa ® 4 mg for at least 15 minutes, the possibility of renal function is maintained.

Increased serum creatinine concentration is also observed in some patients during long-term use of Zometa ® at recommended doses, although less frequently.

Since there are limited clinical data on the use of the drug in patients with severe hepatic failure patients, it is not primobolan enanthate possible to give specific guidance for this category of patients.

Cases of osteonecrosis of the jaw in cancer patients on the background of anti-tumor treatment including bisphosphonates. Many patients had signs of local infection-inflammation, including osteomyelitis.Prior to treatment with bisphosphonates is necessary to provide dental examination and appropriate preventive treatments in patients with risk factors (concomitant therapy – chemotherapy, radiation therapy, corticosteroid treatment, concomitant diseases – anemia, coagulopathy, infection with diseases of the oral cavity, poor oral hygiene).

During treatment, these patients should, if possible, to avoid dental procedures. There is no evidence that the interruption of treatment with bisphosphonates before dental surgery reduces the risk of osteonecrosis of the jaw. The treatment plan specific patient should be based on an individual assessment of risk / benefit ratio.

The efficacy and safety of Zometa ® in pediatric patients has not yet been established.

Form release
Concentrate for solution for infusion 4 mg / 5 ml colorless plastic bottles. 1 bottle with instruction on use in carton box.

Storage
at temperatures no higher than 30 ° C.
The drug should be stored out of reach of children.

Shelf life.
3, the
drug should not be used after the expiration date printed on the package.

Patients should also appoint an additional calcium oral dose of 500 mg per day and vitamin D oral dose of 400 ME per day.

Hypercalcemia due to malignancy:
Adults and elderly patients If hypercalcemia (calcium concentration correction in the level of albumin> 12 mg / dL or 3 mmol / l), the recommended dose is 4 mg. Before administration of the drug diluted concentrate (contents of 1 vial) 100 ml of a solution for infusion containing no calcium (0.9% sodium chloride solution or 5% dextrose). Zometa administered intravenously once; infusion duration – at least 15 minutes. To ensure adequate hydration of the patient is recommended prior to the introduction of saline, in parallel or after the infusion of Zometa.

Patients with impaired renal function
hypercalcemia due to malignancy:
A decision on the treatment of Zometa in patients with severe renal impairment should be taken only after careful evaluation of the risk of the drug and the expected benefits of therapy. Patients whose serum creatinine concentration is <400 micromoles / liter or <4.5 mg / dl, no correction is required dosing regime.

Bone metastases are common malignant tumors and multiple myeloma:

Zometa dose depends on the baseline creatinine clearance calculated according to the formula Cockcroft-Gault. Zometa is not recommended in patients with severe renal impairment (creatinine clearance values <30 mL / min).

how can i buy hgh hgh yellow top buy hgh uk
images

primobolan depot

Appetite stimulant vegetable origin (bitterness).Infusion centaury herb increases appetite and stimulates primobolan depot the secretion of digestive glands and the intestine, has a choleretic effect.Applied as bitterness to increase appetite and improve digestion with a reduced secretory function of the gastrointestinal tract in adults.Hypersensitivity to the drug, increased gastric secretion, gastric primobolan depot ulcer and duodenal ulcers, reflux esophagitis, pregnancy, lactation, children under 18 years.

Dosing and Administration
Approximately 5g (1 tablespoon) centaury herb placed in an enamel bowl, pour 200 ml (1 cup) of hot boiled water, close lid and heated in a boiling water bath for 15 minutes, cooled at room temperature for 45 minutes, filtered, the remaining raw materials squeeze. The volume of the resulting infusion was adjusted with boiled water to 200 ml.

Administered orally in the form of heat for 1/2 -. 1/3 cup 2-3 times a day for 30 minutes before a meal
before drinking the infusion must be shaken.

Side effects:
Allergic reactions are possible.

Overdose
If overdose possible dyspeptic disorders (nausea, diarrhea).

Product Form
Grass chopped by 35 g, 40 g, 50 g, 60 g, 75 g, 100 g c cardboard packs the inner pack. For use, folded into the text of the Guide, is embedded in the packet of instructions or text in full is applied to the pack.

Storage conditions
In a dry place, protected from light; prepared infusion – in a cool place no more than 2 days.
Keep out of reach of children!

Shelf life
3 years.
Do not use beyond the expiration date printed on the package.

Conditions of supply of pharmacies
without a prescription.

images (4)

primobolan side effects

The time to reach maximum blood concentration with the / m administered in a dose of 0.5 g and I r is 2 hours and 1 hour; maximum concentration. It penetrates the joints, the tissue of the cardiovascular system, into the abdominal cavity, the kidney and urinary tract, placenta, middle ear, respiratory tract, skin and soft tissue. In small amounts excreted in breast milk. The primobolan side effects concentration in the tissue of the gallbladder and bile is significantly higher than in plasma. When obstruction of the gallbladder bile concentration lower than in plasma. The volume of distribution.
Hypersensitivity to the drug group of cephalosporins and other beta-lactam antibiotics. Pregnancy and lactation. Babies up to 1 month.
Renal / hepatic failure, pseudomembranous colitis, bowel diseases, children under 1 year.

Dosage and administration
Dosage is determined individually taking into account the severity and localization of infection susceptibility, the patient’s age. The drug can be administered intramuscularly, intravenously (bolus or infusion).The average daily dose for adults is 1-4 g; frequency of administration – 3-4 times per day. The maximum daily dose – 6 The average duration of treatment is 7-10 days.
For the prevention of postoperative infection is administered intravenously 1 g for 0.5-1 hours primobolan side effects before the operation, 0.5-1 g during surgery and at 0.5-1 g every . 8 hours during the first day after surgery
in patients with impaired renal function requires a change in dosing regimen based on the values of creatinine clearance (CC): QA 55 mL / min or more, or when the creatinine concentration in the plasma of 1.5 mg% or less can be administered full dose; with CC 54-35 ml / min or serum creatinine concentration in the plasma of 3-1.6 mg% can enter the full dose, but should increase the interval between injections to 8 hours; QC at 34-11 ml / min or plasma creatinine concentration in mg 4.5-3,1% – 01.02 doses at intervals of 12 hours; QC at 10 ml / min or less or plasma creatinine concentration 4.6 mg% or more -. 1/2 the usual dose every 18-24 hours, all the recommended doses are applied after introduction of the initial dose, the respective severity of the infection. Children 1 month of age or older – 20-50 mg / kg / day; in severe infections the dose may be increased to 100 mg / kg / day. Multiplicity of – 3-4 times per day. Children with impaired renal function dosing regimen correction is carried out depending on the QC values: with CC 70-40 ml / min – 60% of the average daily dose and administered every 12 hours; QC at 40-20 ml / min – 25% of the average daily dose with an interval of 12 h; . with KK 5-20 ml / min – 10% of the average daily dose every 24 hours, all the recommended doses are applied after introduction of the initial dose, the respective severity of the infection. Preparation of solutions for intramuscular injection: 0.25 g of product was dissolved in 1 ml of water for injection 0.5 g – in 2 ml of water for injection, 1 g – 4 ml of water for injection or 0.9% sodium chloride solution, or 0.25 -. 0.5% procaine solutionfor intravenous drip preparation is dissolved in 50-100 ml chloride or 0.9% sodium chloride 5.10% dextrose solution, depending on the dose; infusion is carried out for 20-30 minutes (introduction rate of 60-80 drops per minute). For intravenous single bolus dose of 10 ml diluted in 0.9% sodium chloride and injected slowly over 3-5 min. During the breeding vials vigorously shaken until complete dissolution.

 

Side effects: Allergic reaction: pyrexia, rash, urticaria, pruritus, bronchospasm, eosinophilia, angioedema, arthralgia, anaphylactic shock, erythema multiforme, a malignant exudative erythema (Stevens-Johnson syndrome). From the nervous system: cramps Urinary system : in patients with kidney disease when treatment with high doses of cefazolin (6 g) may appear impaired renal function. In these cases, the dose reduced, and treatment is carried out under the control of the dynamics of urea nitrogen and creatinine in the blood. From the digestive system: nausea, vomiting, diarrhea, abdominal pain, pseudomembranous colitis, in rare cases – cholestatic jaundice, hepatitis. From the side of hematopoiesis: leukopenia, neutropenia, thrombocytopenia, thrombocytosis, haemolytic anemia. in the long-term treatment – goiter, superinfection, caused by antibiotic-resistant strains, candidiasis (including oral candidiasis). Laboratory findings: positive Coombs’ test, increased activity of “liver” transaminases, hypercreatininemia, increased prothrombin time. Local reactions: intramuscular injection of the drug, in rare cases -boleznennost the site of injection, by intravenous injection – phlebitis.

 

Overdose symptoms: pain, inflammatory reactions and phlebitis at the injection site; . dizziness, headache, paresthesia, seizures may develop (particularly in patients with kidney disease) Laboratory findings: an increased concentration of creatinine, BUN, liver enzymes and bilirubin; . thrombocytosis treatment: immediately stop the injection of the drug, to carefully monitor the vital functions of the body and the relevant laboratory parameters; therapy – symptomatic. In severe cases it is possible hemodialysis. Peritoneal dialysis is not efficient.

Interaction with other drugs
should not be used cefazolin with antibacterial drugs, have bacteriostatic mechanism of action (tetracyclines, sulfonamides, macrolides, lincosamides, chloramphenicol), because in vitro studies have shown that there is an antagonism between them.
With the simultaneous use of oral anticoagulants or high doses heparin blood clotting parameters need to be monitored. Aminoglycosides increase the risk of kidney damage. Pharmaceutical incompatible with aminoglycosides (mutual inactivation).
Drugs that block tubular secretion, including probenecid, slow excretion, increase the concentration in the blood primobolan side effects and increase the risk of toxic reactions

Cautions
Patients who had a history of allergic reactions to penicillins, carbapenems, may be sensitive to cephalosporin antibiotics. During treatment with cefazolin may receive false-positive direct and indirect Coombs test, as well as false positive reaction on urine glucose. In appointing the drug may increase gastrointestinal disease, particularly colitis. If you have severe persistent diarrhea should take into account the likelihood of developing pseudomembranous colitis associated with the use of antibiotics. In this case, immediately stop treatment cefazolin and prescribed the appropriate treatment (use of drugs affecting peristalsis, are contraindicated).
The safety of preterm infants and children in the first months of life has not been established.

Product form
Powder for solution for intravenous and intramuscular administration of 250 mg, 500 mg and 1,000 mg.
The amount of drug equivalent to 250 mg, 500 mg or 1000 mg of cefazolin, the vial of clear glass, a sealed rubber septum, crimped aluminum cap and closed plastic primobolan side effects lid. 1 bottle with instruction on use is placed in a cardboard box; 5, 20 or 50 vials, together with instructions for use placed in a cardboard box (for hospitals).

Storage:
In a dry, dark place at a temperature no higher than 25 ° C. Do not freeze. List B.
Keep out of reach of children.

Shelf life
2 years.
Do not use after the expiration date. gen shi labs